The mitotic kinesin KIF14 is overexpressed and is a prognostic indicator in multiple cancers. This study examined the effect of Kif14 overexpression on cancer in vivo for the first time, using a transgenic murine retinoblastoma model. Kif14 overexpression accelerated retinoblastoma initiation, growth rate, progression, and total tumor burden in these mice. These findings confirm that Kif14 can promote tumor progression in vivo, further validating KIF14 as an oncogene and potential therapeutic target. 
Introduction
Retinoblastoma is the most common childhood intraocular malignancy, affecting approximately 1 in 17,000 live births, translating to roughly 8,000 new cases a year globally. 1 Retinoblastoma is the prototypic genetic cancer and has long been a major source of scientific discovery. It is typically initiated by the biallelic loss of the RB1 gene, which encodes the tumor suppressor, pRB. Although the biallelic loss of RB1 is (usually) necessary, it is not sufficient to induce retinoblastoma, instead leading to the benign retinoma. 2 Subsequent mutational events are vital to evolve retinoma to retinoblastoma, including somatic gain of chromosome 1q32. 2, 3 The minimal region of gain at 1q32 contains KIF14, which represents a candidate oncogene in the development of retinoblastoma. 4 The KIF14 locus is gained in >50% of retinoblastomas, 5 and this gene is over-expressed in 90% of retinoblastomas. 4, 6 KIF14 is a member of the kinesin superfamily; 7 kinesins are molecular motors involved in intracellular transport. KIF14 is essential for cytokinesis, interacting with and helping to localize protein regulator of cytokinesis 1 (PRC1) and citron kinase (CIT). 8 However KIF14 also has cytokinesis independent roles, including negative regulation of Rap1a-Radil signaling at the cell membrane. 9 Although the exact molecular functions of KIF14 are still under investigation, a large body of evidence implicates it as an oncogene. 10 It is gained at the DNA level in tumors such as hepatocellular, renal, and ovarian carcinoma. 10 It is overexpressed in multiple cancer types such as breast (including in premalignant breast tissue of BRCA1/2 mutation carriers), 11 lung, ovarian, hepatocellular, and brain tumors. Moreover, in these cancers KIF14 levels are prognostic for outcome. KIF14 knockdown decreases tumorigenicity in vitro and in xenografts, while overexpression enhances growth. 10 Despite these exciting findings, the effects of Kif14 overexpression in a transgenic cancer model have not previously been assessed. The recent development of a Kif14 overexpressing transgenic mouse, constitutively expressing Kif14 under a cytomegalovirus promoter, 12 makes such studies possible. Given the importance of KIF14 in human retinoblastoma, we sought to assess the effects of Kif14 overexpression on tumor formation in the widely used simian virus 40 T-antigen expressing mouse model of retinoblastoma (TAg-RB).
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Methods
Animals
All animal experiments were approved by the Indiana University School of 
Imaging
Animal eyes were imaged longitudinally from two weeks (when eyes first opened) to 12 weeks of age. Image-guided optical coherence tomography (OCT) and brightfield funduscopy were performed using a Micron III intraocular imaging system (Phoenix Research Labs; Pleasanton, CA). Animals were sedated with a mix of i.p.
ketamine (17.2 mg/kg) and dexmedetomidine (0.5 mg/kg). Post sedation, the pupils were dilated using 1% tropicamide, followed by application of a topical hypromellose ophthalmic demulcent solution (Gonak; Akorn, Lake Forest, IL), which prevented the drying of the cornea and the formation of cataracts. After imaging the sedation was reversed by i.p. atipamezole (1 mg/kg).
Quantification of OCT Images
In order to quantify the volumes of individual tumors via OCT, we adapted a previously developed ellipsoid volumetric calculation method. 15 The widest sections of the tumors from perpendicular planes were used to calculate ellipsoid volume (V) using the formula V = 4/3πabc where a, b, and c are the radii of the three axes of the ellipsoid. 15 ImageJ 1.49 (http://imagej.nih.gov) was used to measure the radii of each tumour from OCT images.
Eye Preparation and Immunohistochemistry
After intraocular imaging, cohorts of mice were euthanized at 8 and 12 weeks of age. Enucleated eyes were fixed in 4% paraformaldehyde overnight and then transferred to 70% ethanol. The eyes were processed at the Indiana University School of Medicine Histology Core. Whole eyes were embedded in paraffin, then 2-3 papillary-optic nerve 5 µm sections were collected every 300 µm through each globe.
Mayer's hematoxylin and eosin (H&E) staining was performed as previously described, 14 while adjacent sections were left unstained for immunohistochemistry 
Quantification of Immunohistochemistry
Bright-field micrographs were taken with an EVOS-fl digital microscope (AMG, Mill Creek, WA). Adjacent images of the retina on each slide were stitched together using Adobe Photoshop CS4. ImageJ was used to calculate the percent tumor burden as described. 16 Briefly, the image was converted to 8-bit, then the retinal area was traced manually by an investigator masked to genotype, with area recorded by the region of interest function. Subsequently, the auto threshold function was used to select the TAg expressing cells based on IHC staining. Then, the stained pixels within the retina were counted using the measure function to obtain a value for tumor area in pixels. Total tumor area across the 6-7 slides per globe was divided by total retinal area to obtain the percent tumor area. To provide further validation of this approach, tumor areas histopathologically evident by H&E staining were assessed in a similar manner. 
Statistical Analysis
The independent Student's t-test was used to test for differences in tumor number and percent tumor burden between the control eyes and double transgenic eyes harvested at each time point. The extra sum of squares F-test was used to assess if the fitted exponential growth curve was shared between genotypes. All analyses were performed with GraphPad Prism v. 6.0, and differences were considered statistically significant at p < 0.05.
Results
To determine the effect of Kif14 overexpression on tumor growth in a genetic cancer model, we monitored retinoblastoma progression longitudinally in Kif14;TAg- 
Discussion
We show that the overexpression of Kif14 accelerates tumor onset and increases tumor burden and tumor proliferation rate in the TAg-RB retinoblastoma model. This provides strong evidence that KIF14 is indeed an oncogene, when considered in concert with previous clinical, in vitro and xenograft findings. But increased proliferation appears to be at play as well in Kif14 overexpressing cells. Using a novel adaptation of our ellipsoid volumetric quantification method 15 22 But it has not previously been shown that a putative oncogene can accelerate tumor growth in the TAg-RB model, as we have done here.
TAg-RB has a number of advantages over other retinoblastoma mouse models, as it bears strong resemblance to the human tumors. It shares the expression pattern of a number of genes, including Kif14, with the human disease, 17 and it is the most commonly used model of retinoblastoma for preclinical studies. 23 The tumors initiate in the INL, a possible layer of origin of human tumors, and they contain both FlexnerWintersteiner and Homer Wright rosettes, histopathological hallmarks of human retinoblastoma that are not seen together in other mouse models of retinoblastoma. 13 However, the TAg-RB model has limitations. Induced by specific expression of TAg rather than genetic loss of Rb1, it has a different molecular etiology from the human disease. Recent work has shown that human retinoblastoma can arise from a cone precursor, 24 while the TAg-RB cell of origin is a Müller glia with progenitor properties; 17 different cell types might respond differently to Kif14 overexpression.
Moreover, since TAg functionally inactivates p53 and other proteins as well as pRB, TAg-RB cells might be particularly susceptible to a putative anti-apoptotic effect of Kif14 overexpression, whereas the human cell of origin, which may have functional p53, may be less sensitive.
A further limitation of this study is that we used near-congenic rather than completely congenic animals. Thus, we cannot exclude the possibility that a closely linked allele to the Kif14 transgene could contribute to the observed phenotypic differences. To further support our findings, further backcrosses followed by future investigation of Kif14 overexpression in other transgenic retinoblastoma models, and in human cell xenograft models of the disease is warranted. 25 Future high-resolution analyses of multiple human and murine retinoblastoma genomes, and correlation with gene expression, will also help to completely define KIF14's importance in retinoblastomagenesis.
In conclusion, we have demonstrated that overexpression of Kif14 in the TAg-RB model of retinoblastoma enhances tumor formation. We report a sustained and significant increase in percentage tumor burden in double transgenics compared to TAg-RB control eyes shows a non-significant trend towards a difference (p > 0.05; Student's t-test; n = 4-6 per group). (f) Growth rates of centrally located retinoblastomas from Kif14;TAg-RB mice (red lines) (n = 4) and TAg-RB control mice (black lines) (n = 3). Doubling times were significantly different (1.8 vs. 2.9 weeks, p < 0.0001, extra sum of squares F-test). 199x183mm (300 x 300 DPI)
